Prelude Therapeutics (NASDAQ:PRLD) Posts Earnings Results, Misses Expectations By $0.13 EPS

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.13), FiscalAI reports. The firm had revenue of $5.65 million during the quarter, compared to the consensus estimate of $29.00 million.

Prelude Therapeutics Stock Performance

PRLD stock opened at $3.45 on Monday. The firm has a market capitalization of $275.32 million, a PE ratio of -4.73 and a beta of 1.22. Prelude Therapeutics has a 1-year low of $1.29 and a 1-year high of $6.83. The business’s 50 day simple moving average is $4.00 and its 200 day simple moving average is $4.07.

Wall Street Analysts Forecast Growth

PRLD has been the topic of a number of recent analyst reports. Citigroup restated a “market outperform” rating on shares of Prelude Therapeutics in a report on Wednesday, October 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prelude Therapeutics in a research note on Tuesday, October 27th. JPMorgan Chase & Co. assumed coverage on shares of Prelude Therapeutics in a research report on Thursday, September 17th. They issued an “overweight” rating and a $12.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Prelude Therapeutics in a report on Wednesday, July 29th. Finally, Wall Street Zen downgraded shares of Prelude Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 19th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $8.75.

Get Our Latest Research Report on PRLD

Prelude Therapeutics Company Profile

(Get Free Report)

Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.

Featured Stories

Earnings History for Prelude Therapeutics (NASDAQ:PRLD)

Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.